IMMUNITYBIO, INC. Equity Securities, FV-NI, Unrealized Gain (Loss)
IMMUNITYBIO, INC. (IBRX) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-02-23
- IMMUNITYBIO, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was $0.00.
- IMMUNITYBIO, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-03-31 was -$1.00K, a 100.14% decline year-over-year.
- IMMUNITYBIO, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2024-12-31 was -$112.00K.
- IMMUNITYBIO, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2024-09-30 was -$500.00K.
- IMMUNITYBIO, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was $0.00.
- IMMUNITYBIO, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$632.00K.
- IMMUNITYBIO, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was -$1.59M.
- IMMUNITYBIO, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$4.19M.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | ||||
| 2025-03-31 | -$1.00K 10-Q · filed 2025-05-12 | -$113.00K derived: sum of 2 quarters · filed 2026-02-23 | -$613.00K derived: sum of 3 quarters · filed 2026-02-23 | -$1.31M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-12-31 | -$112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$612.00K derived: sum of 2 quarters · filed 2026-02-23 | -$1.31M derived: sum of 3 quarters · filed 2026-02-23 | -$632.00K 10-K · filed 2026-02-23 | |
| 2024-09-30 | -$500.00K 10-Q · filed 2024-11-12 | -$1.20M derived: sum of 2 quarters · filed 2024-11-12 | -$520.00K 10-Q · filed 2025-11-05 | -$1.22M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-06-30 | -$700.00K 10-Q · filed 2024-08-12 | -$15.00K 10-Q · filed 2024-08-12 | -$715.00K derived: sum of 3 quarters · filed 2026-02-23 | -$1.31M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-03-31 | $725.00K 10-Q · filed 2025-05-12 | -$15.00K derived: sum of 2 quarters · filed 2026-02-23 | -$615.00K derived: sum of 3 quarters · filed 2026-02-23 | -$1.01M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2023-12-31 | -$740.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$1.34M derived: sum of 2 quarters · filed 2026-02-23 | -$1.74M derived: sum of 3 quarters · filed 2026-02-23 | -$1.59M 10-K · filed 2026-02-23 | |
| 2023-09-30 | -$600.00K 10-Q · filed 2024-11-12 | -$1.00M derived: sum of 2 quarters · filed 2024-11-12 | -$851.00K 10-Q · filed 2024-11-12 | -$5.22M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | -$400.00K 10-Q · filed 2024-08-12 | -$258.00K 10-Q · filed 2024-08-12 | -$4.62M derived: sum of 3 quarters · filed 2025-03-03 | -$4.02M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $135.00K 10-Q · filed 2024-05-09 | -$4.22M derived: sum of 2 quarters · filed 2025-03-03 | -$3.62M derived: sum of 3 quarters · filed 2025-03-03 | -$5.49M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | -$4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$3.75M derived: sum of 2 quarters · filed 2025-03-03 | -$5.62M derived: sum of 3 quarters · filed 2025-03-03 | -$4.19M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $600.00K 10-Q · filed 2023-11-09 | -$1.27M derived: sum of 2 quarters · filed 2023-11-09 | $162.00K 10-Q · filed 2023-11-09 | -$6.85M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-06-30 | -$1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$452.00K 10-Q · filed 2023-08-08 | -$7.45M derived: sum of 3 quarters · filed 2024-03-19 | -$13.46M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-03-31 | $1.42M 10-Q · filed 2023-05-11 | -$5.58M derived: sum of 2 quarters · filed 2024-03-19 | -$11.59M derived: sum of 3 quarters · filed 2024-03-19 | -$12.03M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2021-12-31 | -$7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$13.01M derived: sum of 2 quarters · filed 2024-03-19 | -$13.45M derived: sum of 3 quarters · filed 2024-03-19 | -$4.62M 10-K · filed 2024-03-19 | |
| 2021-09-30 | -$6.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$6.45M derived: sum of 2 quarters · filed 2022-11-09 | $2.38M 10-Q · filed 2022-11-09 | $4.77M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | -$443.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $8.39M 10-Q · filed 2022-08-08 | $10.78M derived: sum of 3 quarters · filed 2023-03-01 | $10.77M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $8.83M 10-Q · filed 2022-05-10 | $11.22M derived: sum of 2 quarters · filed 2023-03-01 | $11.22M derived: sum of 3 quarters · filed 2023-03-01 | $11.91M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.38M derived: sum of 2 quarters · filed 2023-03-01 | $3.08M derived: sum of 3 quarters · filed 2023-03-01 | $2.88M 10-K · filed 2023-03-01 | -$1.41M 8-K/A · filed 2021-04-22 |
| 2020-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $692.00K derived: sum of 2 quarters · filed 2021-11-12 | $490.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $696.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $494.00K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$202.00K 10-Q · filed 2021-05-14 | ||||
| 2019-12-31 | -$320.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |